Market Overview

UPDATE: Jefferies Raises PT on Abbott Laboratories on Attractive Valuation

Share:
Related ABT
Fast Money Halftime Report Final Trade From March 11
3 Companies That Could Be Negatively Impacted By Johnson & Johnson Sale Of Cordis
Mylan falls on large share sale (Investor's Business Daily)

In a report published Wednesday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Abbott Laboratories (NYSE: ABT), and raised the price target from $40.00 to $42.00.

In the report, Holford noted, “We remain positive on Pharmaceuticals and see valuation as attractive for most stocks. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche and Pfizer remain high conviction Buy ratings. We point to Eli Lilly and GlaxoSmithKline as least preferred names.”

Abbott Laboratories closed on Tuesday at $36.55.

Latest Ratings for ABT

DateFirmActionFromTo
Mar 2015JefferiesMaintainsHold
Feb 2015JefferiesMaintainsHold
Jan 2015BarclaysMaintainsEqual-weight

View More Analyst Ratings for ABT
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (ABT)

Around the Web, We're Loving...